Neoadjuvant therapy of locally advanced gastric cancer.
Treatment of gastric cancer has evolved with the advent of randomized trials demonstrating chemotherapeutic agents with efficacy in advanced disease. Level I evidence supports delivering chemotherapy in the neoadjuvant setting; the data shows improvement in progression-free and overall survival. A clinical response to therapy is associated with improved R0 resection rates, pathologic response, and outcome in patients with locally advanced disease. Early assessment of metabolic response to therapy can potentially be utilized to tailor treatment.
Mezhir
James J
JJ
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. mezhirj@mskcc.org
Tang
Laura H
LH
Coit
Daniel G
DG
D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003663:Decision Trees; D005743:Gastrectomy; D006801:Humans; D020360:Neoadjuvant Therapy; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
D000970:Antineoplastic Agents